Dear Sunil, As you know the NOAC's were all tested with warfarin and there are no direct comparisons of these new drugs. They showed a 10% reduction in all cause mortalityand 50% reduction in ICH..The decision to with drug to choose from will be made by evaluating Kidney function, age and weight. For instance, if one patient has a good renal function (eGFR > 95 mL/min), Edoxaban should not be used. On the other hand if a patient has eGFR < 15 mL/min, you should not use any of the NOAC's and use warfarin instead. Dabigatran is not recommended for patients with chronic gastritis because the pills are coated on acid, and Rivaroxaban is badly tolerated in patients which are lactose intolerant. These are only but a few differences among them.